
Ana Patricia Alcasabas

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4048470/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Resilient health care in global pediatric oncology during the COVIDâ€19 pandemic. Cancer, 2022, 128, 797-807.	4.1	10
2	Global Neuroblastoma Network: An international multidisciplinary neuroblastoma tumor board for resourceâ€limited countries. Pediatric Blood and Cancer, 2022, 69, e29568.	1.5	6
3	Impact of treatment refusal and abandonment on survival outcomes in pediatric osteosarcoma in Southeast Asia: A multicenter study. Pediatric Blood and Cancer, 2022, , e29556.	1.5	1
4	Predictors and Treatment Outcomes of Pediatric Osteosarcoma in Diverse Socioeconomic Backgrounds in Southeast Asia: A Retrospective Multicenter Study. Asian Pacific Journal of Cancer Prevention, 2022, 23, 631-640.	1.2	0
5	LINC-15. Sustaining multidisciplinary care of children with central nervous system tumors during the COVID-19 pandemic. Neuro-Oncology, 2022, 24, i165-i165.	1.2	ο
6	LINC-20. Impact of the COVID-19 pandemic on 30-day mortality and unplanned reoperation rates for pediatric central nervous system tumors. Neuro-Oncology, 2022, 24, i166-i167.	1.2	0
7	#95: Clinical Profile and Outcome of Pediatric Acute Lymphoblastic Leukemia Patients with Tuberculosis at the Philippine General Hospital. Journal of the Pediatric Infectious Diseases Society, 2021, 10, S17-S17.	1.3	0
8	NFâ€E2 mutation as a novel cause for inherited thrombocytopenia. British Journal of Haematology, 2020, 189, e41-e44.	2.5	3
9	Bridging the Gap in Access to Care for Children With CNS Tumors Worldwide. JCO Global Oncology, 2020, 6, 583-584.	1.8	10
10	LINC-23. PRE-OPERATIVE AND POST-OPERATIVE INTERVENTIONS REDUCE RATES OF VENTRICULITIS IN PEDIATRIC BRAIN TUMOR PATIENTS: A PILOT STUDY. Neuro-Oncology, 2020, 22, iii382-iii383.	1.2	0
11	Political priority and pathways to scale-up of childhood cancer care in five nations. PLoS ONE, 2019, 14, e0221292.	2.5	22
12	Improved outcomes in pediatric acute lymphoblastic leukemia (ALL) with adapted treatment intensity: the use of SIOP-PODC ALL regimen 2 in a resource-limited tertiary referral setting. Blood Advances, 2017, 1, 46-48.	5.2	0